Altimmune/ALT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Altimmune

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Ticker

ALT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Vipin Garg

Employees

59

Headquarters

Gaithersburg, United States

Altimmune Metrics

BasicAdvanced
$532M
Market cap
-
P/E ratio
-$1.59
EPS
0.10
Beta
-
Dividend rate
$532M
0.09709
$14.84
$2.09
3.5M
16.546
-49.42%
-54.46%
-53.14%
1,298.721
3.079
3.079
618.99%
9.99%
-62.66%

What the Analysts think about Altimmune

Analyst Ratings

Majority rating from 8 analysts.
Buy

Altimmune Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$24M
-23.10%
Profit margin
0.00%
NaN%

Altimmune Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.39%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.39
-$0.54
-$0.34
-
Expected
-$0.46
-$0.42
-$0.43
-$0.37
-$0.35
Surprise
-31.12%
-8.14%
24.55%
-7.39%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Altimmune stock?

Altimmune (ALT) has a market cap of $532M as of June 20, 2024.

What is the P/E ratio for Altimmune stock?

The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of June 20, 2024.

Does Altimmune stock pay dividends?

No, Altimmune (ALT) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Altimmune dividend payment date?

Altimmune (ALT) stock does not pay dividends to its shareholders.

What is the beta indicator for Altimmune?

Altimmune (ALT) has a beta rating of 0.1. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Altimmune stock price target?

The target price for Altimmune (ALT) stock is $20.57, which is NaN% below the current price of $. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Altimmune stock

Buy or sell Altimmune stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing